Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00768300




Registration number
NCT00768300
Ethics application status
Date submitted
7/10/2008
Date registered
8/10/2008
Date last updated
8/04/2014

Titles & IDs
Public title
(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
Scientific title
ARTEMIS-IPF: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Early Idiopathic Pulmonary Fibrosis (IPF)
Secondary ID [1] 0 0
GS-US-231-0101
Universal Trial Number (UTN)
Trial acronym
ARTEMIS-IPF
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ambrisentan
Treatment: Drugs - Placebo

Experimental: Ambrisentan -

Placebo comparator: Placebo -


Treatment: Drugs: Ambrisentan
Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.

Treatment: Drugs: Placebo
Placebo to match ambrisentan was administered orally once daily.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to Death or Disease (IPF) Progression.
Timepoint [1] 0 0
Up to 48 months
Secondary outcome [1] 0 0
Proportion of Participants With No Disease Progression or Death at 48 Weeks
Timepoint [1] 0 0
Baseline and Week 48
Secondary outcome [2] 0 0
Change in FVC % Predicted at Week 48
Timepoint [2] 0 0
Baseline and Week 48
Secondary outcome [3] 0 0
Change in DLCO % Predicted at Week 48
Timepoint [3] 0 0
Baseline and Week 48
Secondary outcome [4] 0 0
Change in 6MWT at Week 48
Timepoint [4] 0 0
Baseline and Week 48
Secondary outcome [5] 0 0
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the Short-Form 36® (SF-36)
Timepoint [5] 0 0
Baseline and Week 48
Secondary outcome [6] 0 0
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the St. George's Respiratory Questionnaire (SGRQ)
Timepoint [6] 0 0
Baseline and Week 48
Secondary outcome [7] 0 0
Change in Dyspnea Score at Week 48 as Assessed by the Transitional Dyspnea Index (TDI)
Timepoint [7] 0 0
Baseline and Week 48
Secondary outcome [8] 0 0
Percentage of Participants Who Developed PH on Study
Timepoint [8] 0 0
Up to 48 weeks

Eligibility
Key inclusion criteria
* Male or females from 40 to 80 years of age
* Diagnosis of IPF
* Honeycombing (fibrosis in the lung) on high-resolution computerised tomography (HRCT) scan of less than or equal to 5%
* Willing and able to have 2 right heart catheterizations performed
* Willing to have monthly lab tests to monitor liver function
* Able to perform the 6 minute walk test (indicated adequate physical function)
* Must have meet lung function requirements
* Normal liver function tests
* Negative serum pregnancy test
* Willing to use at least 2 reliable methods of contraception
* Able to understand and willing to sign informed consent form
Minimum age
40 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* No restrictive lung disease (other than usual interstitial pneumonia or IPF)
* No obstructive lung disease
* No recent or active respiratory exacerbations
* No recent hospitalization for an IPF exacerbation
* No recent history of alcohol abuse
* Chronic sildenafil (or same drug class) use for pulmonary hypertension
* Chronic treatment with certain medications for IPF within 30 days of randomization
* No other serious medical conditions

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2011
Sample size
Target
Accrual to date
Final
494
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
- Concord
Recruitment hospital [2] 0 0
- Darlinghurst
Recruitment hospital [3] 0 0
- Chermside
Recruitment hospital [4] 0 0
- Woodville
Recruitment hospital [5] 0 0
- Hobart
Recruitment hospital [6] 0 0
- Parkville
Recruitment hospital [7] 0 0
- Prahran
Recruitment hospital [8] 0 0
- Perth
Recruitment postcode(s) [1] 0 0
2139 - Concord
Recruitment postcode(s) [2] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [3] 0 0
4032 - Chermside
Recruitment postcode(s) [4] 0 0
5011 - Woodville
Recruitment postcode(s) [5] 0 0
7000 - Hobart
Recruitment postcode(s) [6] 0 0
3050 - Parkville
Recruitment postcode(s) [7] 0 0
3181 - Prahran
Recruitment postcode(s) [8] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Delaware
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
New Hampshire
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
South Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Utah
Country [27] 0 0
United States of America
State/province [27] 0 0
Virginia
Country [28] 0 0
United States of America
State/province [28] 0 0
Washington
Country [29] 0 0
Argentina
State/province [29] 0 0
Provincia de Buenos Aires
Country [30] 0 0
Argentina
State/province [30] 0 0
Buenos Aires
Country [31] 0 0
Argentina
State/province [31] 0 0
Ciudad Autonoma de Buenos Aires
Country [32] 0 0
Argentina
State/province [32] 0 0
Mar del Plata, Buenos Aires
Country [33] 0 0
Argentina
State/province [33] 0 0
San Miguel de Tucuman
Country [34] 0 0
Austria
State/province [34] 0 0
Graz
Country [35] 0 0
Austria
State/province [35] 0 0
Innsbruck
Country [36] 0 0
Austria
State/province [36] 0 0
Linz
Country [37] 0 0
Austria
State/province [37] 0 0
Wien
Country [38] 0 0
Belgium
State/province [38] 0 0
Anderlecht
Country [39] 0 0
Belgium
State/province [39] 0 0
Bruxelles
Country [40] 0 0
Belgium
State/province [40] 0 0
Leuven
Country [41] 0 0
Belgium
State/province [41] 0 0
Yvoir
Country [42] 0 0
Brazil
State/province [42] 0 0
Belo Horizonte
Country [43] 0 0
Brazil
State/province [43] 0 0
Florianopolis
Country [44] 0 0
Brazil
State/province [44] 0 0
Goiania
Country [45] 0 0
Brazil
State/province [45] 0 0
Porto Alegre
Country [46] 0 0
Brazil
State/province [46] 0 0
Rio de Janeiro
Country [47] 0 0
Brazil
State/province [47] 0 0
Santo Andre
Country [48] 0 0
Brazil
State/province [48] 0 0
Sao Paolo
Country [49] 0 0
Canada
State/province [49] 0 0
Alberta
Country [50] 0 0
Canada
State/province [50] 0 0
British Columbia
Country [51] 0 0
Canada
State/province [51] 0 0
Newfoundland and Labrador
Country [52] 0 0
Canada
State/province [52] 0 0
Quebec
Country [53] 0 0
Canada
State/province [53] 0 0
Toronto
Country [54] 0 0
Chile
State/province [54] 0 0
Santiago
Country [55] 0 0
Chile
State/province [55] 0 0
Talcahuano
Country [56] 0 0
Chile
State/province [56] 0 0
Valparaiso
Country [57] 0 0
Colombia
State/province [57] 0 0
Bogota
Country [58] 0 0
Colombia
State/province [58] 0 0
Floridablanca
Country [59] 0 0
Czech Republic
State/province [59] 0 0
Brno
Country [60] 0 0
Czech Republic
State/province [60] 0 0
Hradec Kralove
Country [61] 0 0
Czech Republic
State/province [61] 0 0
Jihlava
Country [62] 0 0
Czech Republic
State/province [62] 0 0
Liberec
Country [63] 0 0
Czech Republic
State/province [63] 0 0
Olomouc
Country [64] 0 0
Czech Republic
State/province [64] 0 0
Plzen
Country [65] 0 0
France
State/province [65] 0 0
Lille
Country [66] 0 0
France
State/province [66] 0 0
Marseille
Country [67] 0 0
France
State/province [67] 0 0
Montpellier
Country [68] 0 0
France
State/province [68] 0 0
Nice
Country [69] 0 0
France
State/province [69] 0 0
Paris
Country [70] 0 0
France
State/province [70] 0 0
Pessac
Country [71] 0 0
France
State/province [71] 0 0
Rennes
Country [72] 0 0
France
State/province [72] 0 0
Tours
Country [73] 0 0
Germany
State/province [73] 0 0
Berlin
Country [74] 0 0
Germany
State/province [74] 0 0
Coswig
Country [75] 0 0
Germany
State/province [75] 0 0
Donaustauf
Country [76] 0 0
Germany
State/province [76] 0 0
Essen
Country [77] 0 0
Germany
State/province [77] 0 0
Freiburg
Country [78] 0 0
Germany
State/province [78] 0 0
Greifswald
Country [79] 0 0
Germany
State/province [79] 0 0
Heidelberg
Country [80] 0 0
Germany
State/province [80] 0 0
Lowenstein
Country [81] 0 0
Germany
State/province [81] 0 0
Munchen
Country [82] 0 0
Ireland
State/province [82] 0 0
Dublin
Country [83] 0 0
Israel
State/province [83] 0 0
Ashkelon
Country [84] 0 0
Israel
State/province [84] 0 0
Beer-Sheva
Country [85] 0 0
Israel
State/province [85] 0 0
Haifa
Country [86] 0 0
Israel
State/province [86] 0 0
Jerusalem
Country [87] 0 0
Israel
State/province [87] 0 0
Petach Tikva
Country [88] 0 0
Israel
State/province [88] 0 0
Rehovot
Country [89] 0 0
Israel
State/province [89] 0 0
Tel Aviv
Country [90] 0 0
Israel
State/province [90] 0 0
Tel-Hashomer
Country [91] 0 0
Italy
State/province [91] 0 0
Catania
Country [92] 0 0
Italy
State/province [92] 0 0
Forlì
Country [93] 0 0
Italy
State/province [93] 0 0
Milano
Country [94] 0 0
Italy
State/province [94] 0 0
Modena
Country [95] 0 0
Italy
State/province [95] 0 0
Napoli
Country [96] 0 0
Italy
State/province [96] 0 0
Padova
Country [97] 0 0
Italy
State/province [97] 0 0
Palermo
Country [98] 0 0
Italy
State/province [98] 0 0
Roma
Country [99] 0 0
Italy
State/province [99] 0 0
Siena
Country [100] 0 0
Italy
State/province [100] 0 0
Torino
Country [101] 0 0
Mexico
State/province [101] 0 0
Jalisco
Country [102] 0 0
Mexico
State/province [102] 0 0
Nuevo Leon
Country [103] 0 0
Mexico
State/province [103] 0 0
Huixquilucan Edo. de Mexico
Country [104] 0 0
Mexico
State/province [104] 0 0
Mexico City, DF
Country [105] 0 0
Mexico
State/province [105] 0 0
Monterrey
Country [106] 0 0
Mexico
State/province [106] 0 0
Zapopan, Jalisco
Country [107] 0 0
Netherlands
State/province [107] 0 0
Almelo
Country [108] 0 0
Peru
State/province [108] 0 0
Callao
Country [109] 0 0
Peru
State/province [109] 0 0
Lima
Country [110] 0 0
Poland
State/province [110] 0 0
Bydgoszcz
Country [111] 0 0
Poland
State/province [111] 0 0
Lodz
Country [112] 0 0
Spain
State/province [112] 0 0
Andalucia
Country [113] 0 0
Spain
State/province [113] 0 0
Asturias
Country [114] 0 0
Spain
State/province [114] 0 0
Castilla
Country [115] 0 0
Spain
State/province [115] 0 0
Galicia
Country [116] 0 0
Spain
State/province [116] 0 0
Madrid, Communidad de
Country [117] 0 0
Spain
State/province [117] 0 0
Badalona
Country [118] 0 0
Spain
State/province [118] 0 0
Barcelona
Country [119] 0 0
Spain
State/province [119] 0 0
Madrid
Country [120] 0 0
Switzerland
State/province [120] 0 0
Basel
Country [121] 0 0
Switzerland
State/province [121] 0 0
Bern
Country [122] 0 0
Switzerland
State/province [122] 0 0
Lausanne
Country [123] 0 0
United Kingdom
State/province [123] 0 0
South Yorkshire
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Surrey
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Cambridge
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Chelmsford
Country [127] 0 0
United Kingdom
State/province [127] 0 0
Edinburgh
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Glasgow
Country [129] 0 0
United Kingdom
State/province [129] 0 0
Liverpool
Country [130] 0 0
United Kingdom
State/province [130] 0 0
London
Country [131] 0 0
United Kingdom
State/province [131] 0 0
Mancesheter

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Gilead Sciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The ARTEMIS-IPF study was conducted to determine if ambrisentan was effective in delaying disease progression and death in participants with idiopathic pulmonary fibrosis (IPF), to evaluate its safety, and to evaluate its effect on development of pulmonary hypertension, quality of life, and dyspnea (shortness of breath) symptoms in this participant population. Participants were randomized in a 2:1 ratio to receive ambrisentan or placebo, respectively. Participation in the study was to be up to 4 years, depending on how long it would take to enroll participants and observe study events. After randomization, visits to the clinic took place every 3 months, and laboratory procedures were performed every month.
Trial website
https://clinicaltrials.gov/study/NCT00768300
Trial related presentations / publications
Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O'Riordan TG; ARTEMIS-IPF Investigators*. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013 May 7;158(9):641-9. doi: 10.7326/0003-4819-158-9-201305070-00003. Erratum In: Ann Intern Med. 2014 May 6;160(9):658.
Raghu G, Lynch D, Godwin JD, Webb R, Colby TV, Leslie KO, Behr J, Brown KK, Egan JJ, Flaherty KR, Martinez FJ, Wells AU, Shao L, Zhou H, Pedersen PS, Sood R, Montgomery AB, O'Riordan TG. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med. 2014 Apr;2(4):277-84. doi: 10.1016/S2213-2600(14)70011-6. Epub 2014 Feb 18.
Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, Lyman SK, Adamkewicz JI, Smith V, Kaminski N, O'Riordan T. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J. 2014 May;43(5):1430-8. doi: 10.1183/09031936.00141013. Epub 2013 Oct 31.
Public notes

Contacts
Principal investigator
Name 0 0
Ganesh Raghu, MD
Address 0 0
University of Washington, Div. of Pulmonary and Critical Care Medicine Chair
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00768300